UPB Latest News, Press Relases and Analysis

All

Press Releases

3 hours ago - By: Upstream Bio

Upstream Bio to Participate in Upcoming November Investor Conferences

a month ago - By: Upstream Bio

Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug’s Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress

2 months ago - By: Upstream Bio

Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum

2 months ago - By: Benzinga - Mentions: BRKR SLRX PPCB LUNG ...

12 Health Care Stocks Moving In Tuesday's After-Market Session

3 months ago - By: The Motley Fool

Upstream Bio (UPB) Q2 R&D Soars 169%

5 months ago - By: Upstream Bio

Upstream Bio Appoints Stacy Price as Chief Technology Officer

2 months ago - By: Benzinga - Mentions: GSK LYRA

Upstream's New Sinus Treatment Cuts Need For Surgery, Early Trial Finds

2 months ago - By: Upstream Bio

Upstream Bio Reports Positive Top-Line Results from the Phase 2 VIBRANT Trial of Verekitug for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

2 months ago - By: Upstream Bio

Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

3 months ago - By: Upstream Bio

Upstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued Progress

a year ago - By: Upstream Bio

Upstream Bio Announces Pricing of Upsized Initial Public Offering

4 months ago - By: Upstream Bio

Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD)

5 months ago - By: Stocktwits - Mentions: AMGN

Upstream Bio Stock Gets A Boost As New Lung Inflammation Drug Shows Higher Potency

5 months ago - By: Upstream Bio

Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

5 months ago - By: Upstream Bio

Upstream Bio to Present Mechanistic Insights into Verekitug’s Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025

5 months ago - By: Upstream Bio

Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

6 months ago - By: Upstream Bio

Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs

8 months ago - By: Upstream Bio

Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

8 months ago - By: Upstream Bio

Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

11 months ago - By: Upstream Bio

Upstream Bio Announces Addition to Russell 2000® Index

a year ago - By: Upstream Bio

Upstream Bio Announces Closing of $293 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

a year ago - By: Bloomberg

Upstream Bio Shares Rise 26% to Lead Burst of Life Sciences IPOs

a year ago - By: Bloomberg

UPSTREAM BIO INC (UPB) Stock News

UPB Latest News, Press Relases and Analysis

Upstream Bio to Participate in Upcoming November Investor Conferences

Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug’s Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress

Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum

12 Health Care Stocks Moving In Tuesday's After-Market Session

Upstream Bio (UPB) Q2 R&D Soars 169%

Upstream Bio Appoints Stacy Price as Chief Technology Officer

Upstream's New Sinus Treatment Cuts Need For Surgery, Early Trial Finds

Upstream Bio Reports Positive Top-Line Results from the Phase 2 VIBRANT Trial of Verekitug for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Upstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued Progress

Upstream Bio Announces Pricing of Upsized Initial Public Offering

Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD)

Upstream Bio Stock Gets A Boost As New Lung Inflammation Drug Shows Higher Potency

Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

Upstream Bio to Present Mechanistic Insights into Verekitug’s Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025

Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs

Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Upstream Bio Announces Addition to Russell 2000® Index

Upstream Bio Announces Closing of $293 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Upstream Bio Shares Rise 26% to Lead Burst of Life Sciences IPOs

Upstream Bio Leads Three Life Sciences IPOs With Upsized Listing